POA Pharma Scandinavia AB and MERUS LABS INTERNATIONAL INC., expands existing Agreement with Monoket®Isangina®
POA Pharma Scandinavia AB and MERUS LABS INTERNATIONAL INC., expands there existing Promotion & Distribution Agreements for EMSELEX®/ENABLEX® and SALAGEN® with Monoket®Isangina® for the Nordics.
Toronto/Gothenburg, June 30, 2016 – Merus Labs International Inc. [TSX: MSL, NASDAQ: MSLI] is pleased to announce that through its wholly owned subsidiaries, Merus Labs B.V and Merus Labs Luxco S.à R.L., it has entered into promotion and distribution agreements with POA Pharma Scandinavia AB for the Merus Labs Monoket/Isangina® product.
POA Pharma Scandinavia AB has been granted exclusive rights to distribute,Monoket/Isangina® in the Nordics defined collectively as Denmark, Norway, Sweden, Finland, and Iceland.
Monkey/Isangina® with its indication, for the prophylaxis and long term management of angina pectoris
Coronary artery disease, preventive treatment in angina pectoris and severe heart failure (NYHA III-IV) especially caused due to coronary artery disease.
The product has it´s place in our competence area Cardiology and we are happy being able to increase our cooperation with an exiting, international partner, as Merus Lab”, says Tina Madsen CEO at POA.
Frank Rotmann, VP & Head of European Operations: ”With our defined strategy utilizing our expertise in pharmaceutical markets in Europe and our access to capital to acquire and license specialty care branded products, it is crucial having a stable partner in the interesting Nordic market.”
Merus Labs International Inc. is a specialty pharmaceutical company engaged in the acquisition and licensing of pharmaceutical products. The Company utilizes its expertise in pharmaceutical markets and its access to capital to acquire and license niche branded products. Merus further enhances the sale and distribution of these products by the introduction of a focused marketing and promotion plan.
POA Pharma Scandinavia. POA is a young Boutique Health care company, 5 years old, with offices in the four Nordic countries and in USA. POA stands for Point of Action, new ideas and new combinations and is occupied within three strategic areas:
1. The Nordics were POA represent 14 Pharmaceutical producers from 11 countries. The products are placed in 9 areas of Competence – therapy sections.
2. Central marketing and development of own products.
3. Export with distribution agreement with 40 countries.
For further information please contact:
Merus Labs International Inc.
Frank Rotmann, VP & Head of European Operations
Merus Labs Luxco S.à R.L.
Tel: + 352 27 112 7044
Tina Madsen Sandström, CEO, POA Pharma Scandinavia AB
Tel: +46 (0) 31788 05 99